Skip to content

Randomized controlled trial of Jinkui Zexie Decoction in the treatment of benign paroxytic positional vertigo

Randomized controlled trial of Jinkui Zexie Decoction in the treatment of benign paroxytic positional vertigo

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005043
Enrollment
Unknown
Registered
2021-07-11
Start date
2021-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign paroxytic positional vertigo

Interventions

Sponsors

China Academy of Chinese Medical Scicences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years, with normal behavior; 2. Meet the diagnostic criteria, of which the TCM diagnostic criteria must be determined by two senior TCM physicians based on syndrome differentiation; 3. The Chinese version of the Vertigo Disability Assessment Scale (DHI) score, E value>18 points; 4. The study was ethically reviewed, and all the enrolled patients signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Brain trauma stroke; blood disease stroke; severe rheumatic heart disease complicated with atrial fibrillation; 2. Combined with cervical spine, craniocerebral space-occupying lesions, liver and kidney system diseases; mental illness; 3. Pregnancy; 4. Those who are allergic to drugs; 5. Cases of taking other traditional Chinese medicines (including decoctions, proprietary Chinese medicines, etc.) at the same time.

Design outcomes

Primary

MeasureTime frame
Vertigo Disability Rating Scale Score;

Secondary

MeasureTime frame
Clinical symptom evaluation scale score of vertigo;

Countries

China

Contacts

Public ContactJing Zhiwei

China Academy of Chinese Medical Scicences

drjzw@163.com+86 10 64089827

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026